Overview

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Status:
Completed

Trial end date:
2020-06-24

Target enrollment:

Participant gender:

Summary

This is a pilot, single center, open-label study to examine the ORR, safety, and toxicity of avelumab in combination with SAR in non-responding and progressing NSCLC patients previously treated with a PD-1 Inhibitor.

Phase:

Early Phase 1

Details

Lead Sponsor:

Megan Daly, MD
University of California, Davis

Collaborator:

EMD Serono

Treatments:

Avelumab